Notably, the expression levels of VMP1 decrease in correlation with the progression of PD; however, this reduction can be mitigated through the administration of agonists targeting dopamine receptors (Al-Nusaif et al., 2022). This evidence concerns the gene VMP1 and Parkinson disease.